Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAINASDAQ:AUPHNASDAQ:BGMNASDAQ:ELVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Life Sciences$1.39+0.7%$1.42$1.03▼$2.57$277.72M1.221.51 million shs1.12 million shsAUPHAurinia Pharmaceuticals$8.10-0.3%$8.04$4.99▼$10.67$1.11B1.161.33 million shs889,734 shsBGMQilian International Holding Group$11.28+0.7%$10.64$5.26▼$14.78$1.10B1.3327,346 shs1,611 shsELVNEnliven Therapeutics$18.28-7.1%$19.11$13.30▼$30.03$897.07M1.07259,638 shs254,358 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Life Sciences-6.12%-2.13%+5.34%-43.67%-34.91%AUPHAurinia Pharmaceuticals-1.51%+0.18%+4.16%-1.63%+57.66%BGMQilian International Holding Group-3.75%-3.15%+0.56%+2.08%+1,077,999,900.00%ELVNEnliven Therapeutics-3.43%+5.58%+5.35%-13.45%-14.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATAIAtai Life Sciences2.215 of 5 stars3.51.00.00.00.63.31.3AUPHAurinia Pharmaceuticals2.559 of 5 stars3.52.00.00.02.00.81.9BGMQilian International Holding GroupN/AN/AN/AN/AN/AN/AN/AN/AELVNEnliven Therapeutics2.0008 of 5 stars3.60.00.00.02.14.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIAtai Life Sciences 3.00Buy$10.50655.40% UpsideAUPHAurinia Pharmaceuticals 3.00Buy$11.5042.06% UpsideBGMQilian International Holding Group 0.00N/AN/AN/AELVNEnliven Therapeutics 3.25Buy$40.33120.61% UpsideCurrent Analyst Ratings BreakdownLatest ATAI, AUPH, BGM, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $39.003/19/2025ATAIAtai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.002/13/2025ATAIAtai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIAtai Life Sciences$308K901.67N/AN/A$1.47 per share0.95AUPHAurinia Pharmaceuticals$235.13M4.70N/AN/A$2.63 per share3.08BGMQilian International Holding Group$25.10M43.68N/AN/A$6.10 per share1.85ELVNEnliven TherapeuticsN/AN/AN/AN/A$5.97 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIAtai Life Sciences-$40.22M-$0.93N/AN/AN/AN/A-65.75%-52.71%5/13/2025 (Estimated)AUPHAurinia Pharmaceuticals-$78.02M$0.05N/A14.46N/A-10.23%-4.41%-3.07%5/12/2025 (Confirmed)BGMQilian International Holding Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/AELVNEnliven Therapeutics-$71.58M-$1.89N/AN/AN/AN/A-29.46%-27.33%5/13/2025 (Estimated)Latest ATAI, AUPH, BGM, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025ATAIAtai Life Sciences-$0.19N/AN/AN/AN/AN/A5/13/2025Q1 2025ELVNEnliven Therapeutics-$0.51N/AN/AN/AN/AN/A3/17/2025Q4 2024ATAIAtai Life Sciences-$0.14-$0.24-$0.10-$0.24$0.30 million($0.01) million3/13/2025Q4 2024ELVNEnliven Therapeutics-$0.53-$0.46+$0.07-$0.46N/A$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATAIAtai Life SciencesN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ABGMQilian International Holding GroupN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIAtai Life Sciences0.145.815.81AUPHAurinia Pharmaceuticals0.175.605.11BGMQilian International Holding GroupN/A3.392.82ELVNEnliven TherapeuticsN/A17.4417.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIAtai Life Sciences28.41%AUPHAurinia Pharmaceuticals36.83%BGMQilian International Holding GroupN/AELVNEnliven Therapeutics95.08%Insider OwnershipCompanyInsider OwnershipATAIAtai Life Sciences31.20%AUPHAurinia Pharmaceuticals4.30%BGMQilian International Holding Group58.66%ELVNEnliven Therapeutics29.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIAtai Life Sciences80199.80 million115.45 millionOptionableAUPHAurinia Pharmaceuticals300136.65 million137.02 millionOptionableBGMQilian International Holding Group29897.22 million2.48 millionN/AELVNEnliven Therapeutics5049.07 million34.59 millionOptionableATAI, AUPH, BGM, and ELVN HeadlinesRecent News About These CompaniesEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Joseph P. Lyssikatos Sells 5,030 SharesMay 6 at 4:25 AM | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Decreased by Ally Bridge Group NY LLCMay 4 at 7:45 AM | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by 5AM Venture Management LLCMay 4 at 7:22 AM | marketbeat.comAcuta Capital Partners LLC Decreases Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)May 4 at 7:11 AM | marketbeat.comBoxer Capital Management LLC Acquires New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)May 4 at 6:25 AM | marketbeat.comRA Capital Management L.P. Sells 212,247 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)May 3, 2025 | marketbeat.comMarshall Wace LLP Sells 96,624 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)May 3, 2025 | marketbeat.comWhat Does Enliven Therapeutics Mean for the NASDAQ Composite Today?May 2, 2025 | kalkinemedia.comBenjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMay 1, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Boothbay Fund Management LLCApril 30, 2025 | marketbeat.comLord Abbett & CO. LLC Raises Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)April 30, 2025 | marketbeat.comArtia Global Partners LP Makes New Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN)April 29, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Adage Capital Partners GP L.L.C.April 29, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Trading 10.8% Higher - Should You Buy?April 24, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $80,350.00 in StockApril 24, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 5,000 SharesApril 23, 2025 | marketbeat.comEnliven Therapeutics: Awaiting Additional Trial DataApril 22, 2025 | seekingalpha.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells 5,000 Shares of StockApril 22, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Fmr LLCApril 15, 2025 | marketbeat.comFederated Hermes Inc. Takes $2.65 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)April 15, 2025 | marketbeat.comVanguard Group Inc. Purchases 55,283 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)April 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATAI, AUPH, BGM, and ELVN Company DescriptionsAtai Life Sciences NASDAQ:ATAI$1.39 +0.01 (+0.72%) Closing price 04:00 PM EasternExtended Trading$1.39 0.00 (0.00%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Aurinia Pharmaceuticals NASDAQ:AUPH$8.10 -0.03 (-0.31%) Closing price 03:59 PM EasternExtended Trading$8.10 +0.00 (+0.06%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Qilian International Holding Group NASDAQ:BGM$11.28 +0.08 (+0.67%) Closing price 03:58 PM EasternExtended Trading$11.28 0.00 (0.00%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Enliven Therapeutics NASDAQ:ELVN$18.28 -1.41 (-7.15%) Closing price 03:59 PM EasternExtended Trading$18.30 +0.01 (+0.07%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
